亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study

医学 化疗 抗体 肿瘤科 内科学 临床研究阶段 抗体疗法 癌症研究 免疫疗法 化疗方案 免疫学 病理 抗体反应 单克隆抗体
作者
Shuang Huang,Feng Liu,Song Qu,Lisha Chen,Ping Zhou,Shenhong Qu,Xiaohong Ai,Yong Chen,Meilian Liu,Rensheng Wang,Kelvin KW Chan,Peng Zhang,Chunhong Hu,Jiyu Wen,Jian Zhang,Wen Liu,Xiaojiang Li,Kangsheng Gu,Li Xiang,Dongxia Wang
出处
期刊:Signal Transduction and Targeted Therapy [Springer Nature]
卷期号:11 (1) 被引量:10
标识
DOI:10.1038/s41392-026-02645-0
摘要

In this phase 3 trial, penpulimab combined with chemotherapy was assessed against a regimen of placebo plus chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma (R/M NPC). 291 patients were randomised and allocated in a 1:1 ratio in order to receive penpulimab (n = 144; 200 mg) or placebo (n = 147; 200 mg), plus chemotherapy (cisplatin/carboplatin and gemcitabine) every 3 weeks. Patients followed by maintenance therapy with penpulimab or placebo after 6 cycles. The primary endpoint of this study was progression-free survival (PFS) according to RECIST v1.1, and a significantly longer median PFS in the penpulimab arm versus the placebo arm (9.63 versus 7.00 months; hazard ratio 0.45, 95% CI: 0.33-0.62, P < 0.0001) was demonstrated in this prespecified interim analysis. The key secondary endpoint was the overall survival (OS). However, the OS data were still immature, and the median OS was not achieved (hazard ratio, 0.94; 95% CI: 0.63-1.40). The occurrence of treatment-related adverse events (grade ≥ 3) was 89.0% and 85.9% in two arms, with the most common being reduced the quantity of neutrophil (56.2% vs. 62.0%), reduced the quantity of white blood cell (54.1% vs. 54.9%), and anemia (45.2% vs. 38.7%). In the penpulimab arm, 6 patients (4.1%) experienced immune-related adverse events (grade ≥ 3). Adding penpulimab to chemotherapy led to a notable enhancement in PFS for the first-line R/M NPC treatment, alongside a safety profile that was both manageable and tolerable. ClinicalTrials.gov identifier NCT04974398.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
冷酷的祥完成签到,获得积分10
刚刚
刘承昭发布了新的文献求助10
3秒前
白rain完成签到,获得积分10
5秒前
wanci的应助被刘承昭采纳,获得10
6秒前
9秒前
10秒前
CipherSage的应助被DRJ采纳,获得10
11秒前
PennPeak完成签到,获得积分10
11秒前
甜甜的悲发布了新的文献求助10
13秒前
甜甜的悲发布了新的文献求助10
13秒前
13秒前
甜甜的悲发布了新的文献求助10
15秒前
甜甜的悲发布了新的文献求助10
16秒前
16秒前
甜甜的悲发布了新的文献求助10
16秒前
16秒前
甜甜的悲发布了新的文献求助10
17秒前
17秒前
17秒前
甜甜的悲发布了新的文献求助10
19秒前
19秒前
甜甜的悲发布了新的文献求助10
19秒前
19秒前
甜甜的悲发布了新的文献求助10
19秒前
甜甜的悲发布了新的文献求助10
19秒前
20秒前
甜甜的悲发布了新的文献求助10
20秒前
21秒前
21秒前
Akim的应助被迷人宛亦采纳,获得10
22秒前
甜甜的悲发布了新的文献求助10
22秒前
22秒前
22秒前
23秒前
甜甜的悲发布了新的文献求助10
23秒前
23秒前
甜甜的悲发布了新的文献求助10
23秒前
甜甜的悲发布了新的文献求助10
23秒前
23秒前
甜甜的悲发布了新的文献求助10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165968
求助须知:如何正确求助?哪些是违规求助? 9559396
关于积分的说明 21749984
捐赠科研通 7756746
什么是DOI,文献DOI怎么找? 3429092
关于科研通互助平台的介绍 2553386
邀请新用户注册赠送积分活动 2473667